1. Home
  2. MP vs PCVX Comparison

MP vs PCVX Comparison

Compare MP & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MP Materials Corp.

MP

MP Materials Corp.

HOLD

Current Price

$72.90

Market Cap

10.3B

ML Signal

HOLD

Logo Vaxcyte Inc.

PCVX

Vaxcyte Inc.

HOLD

Current Price

$56.72

Market Cap

8.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MP
PCVX
Founded
2017
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.3B
8.6B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
MP
PCVX
Price
$72.90
$56.72
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
4
Target Price
$75.25
$88.25
AVG Volume (30 Days)
5.1M
1.0M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
12.28
N/A
EPS
N/A
N/A
Revenue
$331,952,000.00
N/A
Revenue This Year
$100.51
N/A
Revenue Next Year
$60.41
N/A
P/E Ratio
N/A
N/A
Revenue Growth
147.15
N/A
52 Week Low
$18.64
$28.64
52 Week High
$100.25
$65.00

Technical Indicators

Market Signals
Indicator
MP
PCVX
Relative Strength Index (RSI) 67.49 43.34
Support Level $59.06 $52.04
Resistance Level $74.18 $58.95
Average True Range (ATR) 4.24 2.28
MACD 0.76 -0.59
Stochastic Oscillator 98.01 29.01

Price Performance

Historical Comparison
MP
PCVX

About MP MP Materials Corp.

MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America. The company is also developing a rare earth metal, alloy, and magnet manufacturing facility in Fort Worth, Texas. The company's operations are organized into two reportable segments: Materials and Magnetics.

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Share on Social Networks: